ArticleTranslational cancer research2026
Enhanced CT-based deep learning radiomics and biological correlations for predicting immunotherapy efficacy in advanced non-small cell lung cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identifying predictive markers for immunotherapy in non-small cell lung cancer (NSCLC) is critical for personalized treatment. This study aimed to construct a predictive model that integrates clinical features, enhanced computed tomography (CT)-radiomics, and deep learning (DL) features for the assessment of durable clinical benefit (DCB) from immunotherapy in patients with advanced NSCLC and to provide biological interpretability to predictions by integrating radiogenomic data. Methods: We conducted a retrospective analysis of 201 advanced NSCLC patients who underwent immunotherapy with CT images, with data supplemented from The Cancer Imaging Archive (TCIA). Radiomics features (RFs) were extracted from enhanced CT images, and DL features were derived using a pre-trained ResNet-34 model. DCB-related signatures were constructed using the least absolute shrinkage and selection operator (LASSO) algorithm, and fusion nomogram models were developed by integrating significant clinical variables, radiomics, and DL features. Shapley additive explanations were employed to quantify the impact of radiomics-DL features on model predictions. Gene set enrichment and biological correlation analyses based on transcriptomic TCIA data were performed to explore the biological significance of radiomics-DL score. Results: Statistically significant clinical predictors included initial efficacy, brain metastases, programmed death-ligand 1 (PD-L1) expression, and hemoglobin levels. The fusion nomogram model demonstrated the highest predictive accuracy for DCB, with area under the curve (AUC) values of 0.843 in the train cohort and 0.894 in the test cohort, surpassing individual feature sets. Biological exploration revealed associations between radiomics-DL score and biological characteristics, including immune responses and immunoregulation. Conclusions: This integrated approach shows the potential of combining clinical, radiomics and deep learning features (DLFs) as a noninvasive biomarker for predicting immunotherapy efficacy in NSCLC, assisting in patient selection and clinical decision-making. Radiotranscriptomic analysis may reveal key cellular and immune patterns associated with radiomics-DL signature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.